Home > Treatment Options > Tumor Suppressors > Clinical Trials >

Everolimus (Afinitor™)

Last Updated: 03/6/19

Status: Currently a NF2 Clinical Trial


Chemical Structure, RAD001

Trade Name: Afinitor™ FermentekTM
Synonyms: RAD-001, RAD001, Certican, Afinitor, Zortress, Sirolimus,
SDZ-RAD, RAD001, Everolimus [USAN], RAD 001, Rapamycin,
42-O-(2-hydroxyethyl)-, UNII-9HW64Q8G6G
Pharmaceutical Company: Novartis
Legal Status: ℞ - Trial
Administered By: Pill - Oral
Tumor Target: Vestibular Schwannoma
Protein Target: mTOR Inhibitors - specifically mTORC1
Formula: C53H83NO14
NF2 Trials:
PubChem CID 6442177
ChemSpider 21106307

Side Effects

Infections, anemia, anorexia, hyperglycemia, hyperlipidemia, headache, pneumonitis, epistaxis, GI disorders.

Most common reason of inability to remain on Everolimus was irritation of Mucous Membranes. Mucous Membranes an epithelial tissue that secretes mucus and that lines many body cavities and tubular organs including the gut and respiratory passages. - mouth or on the genitals.

Common Side Effects

  • Lung and Breathing Problems
  • Infections
  • Kidney Failure
  • Mouth Ulcers
  • Liver problems
  • Vaccinations - patients should not have live vaccinations while on Afinitor
  • Contraindicated with certain medications and certain foods

Additional Possible Side Effects:

  • Mouth Ulcers
  • Feeling Weak
  • Cough
  • Shortness of Breath
  • Diarrhea
  • Rash, Dry Skin, Itching
  • Nausea and Vomiting
  • Fever
  • Loss of Appetite
  • Swelling - Arms, Legs, Feet or Ankles
  • Infections - Respiratory Tract, Sinuses and Ears
  • Constipation
  • Stomach pain
  • Seizure
  • Headache
  • Dizziness
  • Stuffy / Runny Nose
  • change in personality
  • Low White Cell Count
  • High Fat Content in Blood

Other Uses

  • Advanced Kidney Cancer
  • Renal Transplantorgan Rejection Prevention
  • Subependymal Giant Cell Astrocytoma (SEGA)
  • Progressive / Metastatic Pancreatic Neuroendocrine Tumors
  • Breast Cancer

Sources

Ketoconazole 2%S
What is NF2? | About Us | Treatment Options | Sitemap

Disclaimer: Neurofibromatosis Type 2 - Information and Services, www.nf2is.org, is not run by medical experts, affiliated with any healthcare organization or any other company. No assurance can be made to the accuracy or completeness of the information provided here, the accuracy of other sites to which this site links, or of sites that link to this site. - Read More

Copyright © 2008 - 2019